Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK112 and AK104 with or without chemotherapy in advanced non-small cell lung cancer
CTR20231445Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jul 2023; status: active.
02
Drugs
ivonescimabcadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231445.